WELDON SPRING — Pharmaceutical companies Pfizer and Valneva announced plans to seek regulatory approval for a four-dose vaccine designed to protect against Lyme disease. The vaccine candidate has demonstrated approximately 75% effectiveness in reducing cases, according to the companies.

This initiative follows an announcement in May by Health and Human Services Secretary Robert F. Kennedy Jr. regarding a new initiative to combat Lyme disease. The Centers for Disease Control and Prevention reports that around 476,000 individuals in the U.S. may be diagnosed and treated for Lyme disease each year. A previous Lyme disease vaccine was introduced in the late 1990s but was withdrawn three years later.

Lyme disease, if left untreated, can lead to symptoms such as fevers, chills, headaches, arthritis, shooting pains, and inflammation of the brain and spinal cord. Hunter Jess Manganelli experienced muscle weakness, tiredness, fatigue, swelling, and headaches approximately two years ago after a tick bite.

Steven Rinella, an author and conservationist, and his older son contracted Lyme disease 13 years ago during a fishing trip in the Hudson Valley, New York. Rinella's son developed Bell's palsy, but recovered following oral antibiotic treatment. Rinella himself received a month of intravenous antibiotic treatments for the disease.

Rinella stated, "I thought my life had changed, but I recovered, as far as I know." He described the prevalence of ticks in his outdoor activities, noting, "I'm a turkey hunter. In talking about turkey hunting, you talk about ticks as much as you talk about turkeys."

Julian Barnes, another hunter, expressed his perspective on a new vaccine. "I would say I am vaccine-hesitant, generally speaking. But Lyme, I've seen the way it affects people in my life," Barnes said. "I would definitely have to really understand the vaccine, how it works," he added. Manganelli also indicated interest in a vaccine, stating, "Given my proclivity for the outdoors, absolutely."

Why It Matters

The potential introduction of a new Lyme disease vaccine comes as public health officials continue to address the widespread impact of the illness. With nearly half a million people potentially diagnosed and treated annually in the U.S., a vaccine could offer a preventative measure against a disease that can cause a range of severe symptoms. The federal government's recent initiative highlights the ongoing focus on managing and mitigating Lyme disease nationally.